Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

开始日期2021-03-01

申办/合作机构

RevImmune, Inc.

NCT04426201 / Terminated临床2期

A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort

Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients

开始日期2020-12-20

申办/合作机构

RevImmune, Inc.

[+4]

NCT04154826 / Terminated临床2期

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease. Two Doses Phase II, Single Center, Open-label Trial

A prospective, single-center, single-blinded study involving patients with refractory nontuberculous mycobacteria lung disease to ascertain pharmacokinetics, safety, efficacy, and tolerability of two dose levels of parenteral administration of recombinant Interleukin-7 (IL-7) (CYT107).

开始日期2020-11-30

申办/合作机构

RevImmune, Inc.

[+1]

100 项与 Interleukin-7(Cytheris SA) 相关的临床结果

登录后查看更多信息

100 项与 Interleukin-7(Cytheris SA) 相关的转化医学

登录后查看更多信息

100 项与 Interleukin-7(Cytheris SA) 相关的专利（医药）

登录后查看更多信息

643

项与 Interleukin-7(Cytheris SA) 相关的文献（医药）

2024-01-01·Cellular immunology

Development of a highly cytotoxic, clinical-grade virus-specific T cell product for adoptive T cell therapy

Article

作者: Rocha, Fernanda Agostini ; Hamerschlak, Nelson ; Silveira, Caio Raony Farina ; Marti, Luciana Cavalheiro ; Dos Santos, Ancély Ferreira ; Stefanini, Ana Carolina Buzzo

At present, recipients of allogeneic hematopoietic stem-cells are still suffering from recurrent infections after transplantation. Infusion of virus-specific T cells (VST) post-transplant reportedly fights several viruses without increasing the risk of de novo graft-versus-host disease. This study targeted cytomegalovirus (CMV) for the development of an innovative approach for generating a very specific VST product following Good Manufacturing Practices (GMP) guidelines. We used a sterile disposable compartment named the Leukoreduction System Chamber (LRS-chamber) from the apheresis platelet donation kit as the starting material, which has demonstrated high levels of T cells. Using a combination of IL-2 and IL-7 we could improve expansion of CMV-specific T cells. Moreover, by developing and establishing a new product protocol, we were able to stimulate VST proliferation and favors T cell effector memory profile. The expanded VST were enriched in a closed automated system, creating a highly pure anti-CMV product, which was pre-clinically tested for specificity in vitro and for persistence, biodistribution, and toxicity in vivo using NOD scid mice. Our results demonstrated very specific VST, able to secrete high amounts of interferon only in the presence of cells infected by the human CMV strain (AD169), and innocuous to cells partially HLA compatible without viral infection.

2024-02-01·Molecular therapy : the journal of the American Society of Gene Therapy

Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression

Article

作者: Awuah, Dennis ; Wang, Xiuli ; Vyas, Vibhuti ; Lim, Laura ; Priceman, Saul J ; Taus, Ellie ; Jin, Katherine ; Hsieh, Hui-Ju ; Munoz, Ashlie M ; Clark, Mary C ; Lin, Shu-Hong ; Goldberg, Lior ; Urak, Ryan ; Forman, Stephen J

Dexamethasone (dex) is a glucocorticoid that is a mainstay for the treatment of inflammatory pathologies, including immunotherapy-associated toxicities, yet the specific impact of dex on the activity of CAR T cells is not fully understood. We assessed whether dex treatment given ex vivo or as an adjuvant in vivo with CAR T cells impacted the phenotype or function of CAR T cells. We demonstrated that CAR T cell expansion and function were not inhibited by dex. We confirmed this observation using multiple CAR constructs and tumor models, suggesting that this is a general phenomenon. Moreover, we determined that dex upregulated interleukin-7 receptor α on CAR T cells and increased the expression of genes involved in activation, migration, and persistence when supplemented ex vivo. Direct delivery of dex and IL-7 into tumor-bearing mice resulted in increased persistence of adoptively transferred CAR T cells and complete tumor regression. Overall, our studies provide insight into the use of dex to enhance CAR T cell therapy and represent potential novel strategies for augmenting CAR T cell function during production as well as following infusion into patients.

2023-12-01·Leukemia

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies

Article

作者: Cooper, Matthew L ; O' Neal, Julie ; Staser, Karl W ; Carter, Alun J ; DiPersio, John F ; Ritchey, Julie K ; Devenport, Jessica M ; Turk, Rolf ; Rettig, Garrett ; Lee, Byung Ha ; Rettig, Michael P ; Xiang, Jingyu ; Gao, Feng ; Kim, Miriam Y

Abstract:

T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic “universal” CD2-targeting CAR-T cell (UCART2), in which the CD2 antigen is deleted to prevent fratricide, and the T-cell receptor is removed to prevent GvHD. UCART2 demonstrated efficacy against T-ALL and CTCL and prolonged the survival of tumor-engrafted NSG mice in vivo. To evaluate the impact of CD2 on CAR-T function, we generated CD19 CAR-T cells (UCART19) with or without CD2 deletion, single-cell secretome analysis revealed that CD2 deletion in UCART19 reduced frequencies of the effector cytokines (Granzyme-B and IFN-γ). We also observed that UCART19ΔCD2 had reduced anti-tumor efficacy compared to UCART19 in a CD19+NALM6 xenograft model. Of note is that the reduced efficacy resulting from CD2 deletion was reversed when combined with rhIL-7-hyFc, a long-acting recombinant human interleukin-7. Treatment with rhIL-7-hyFc prolonged UCART2 persistence and increased survival in both the tumor re-challenge model and primary patient T-ALL model in vivo. Together, these data suggest that allogeneic fratricide-resistant UCART2, in combination with rhIL-7-hyFc, could be a suitable approach for treating T-cell malignancies.

项与 Interleukin-7(Cytheris SA) 相关的新闻（医药）

2024-06-04

·PRNewswire

EMA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome

This regulatory milestone marks an acceleration of the process around NT-I7's potential first indication, after other recent positive news. NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the immunosuppressive effects of ARS. ROCKVILLE, Md. , June 4, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to NT-I7 (efineptakin alfa) for the treatment of Acute Radiation Syndrome (ARS). This regulatory milestone follows the ODD granted to NT-I7 by the FDA in the US for the same indication in November 2023. It is the second ODD received by NT-I7 from the EMA, following the one granted in Idiopathic CD4+ Lymphocytopenia (ICL) in May 2017. ARS is a critical condition resulting from a high dose of radiation exposure, causing severe, sometimes fatal damage to the bone marrow and the immune system. Currently, there are no treatments available that effectively promote T cell recovery after such exposure. NT-I7, a novel long-acting human interleukin-7 (IL-7), has shown promise to accelerate T cell reconstitution and enhance the immune response, offering a potential solution for this medical unmet need. Clinical studies have shown that NT-I7 significantly boosts T cell counts, while maintaining a high level of safety and tolerability. NeoImmuneTech is actively developing NT-I7 in ARS through partnerships with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and Duke University. Recently, Duke University secured a $6 million grant from NIAID for NT-I7 development in ARS. Luke Oh, Ph.D., President and Chief Executive Officer of NeoImmuneTech, said: "We are thrilled to see the deep interest of the scientific and regulatory community around the potential use of NT-I7 as a medical countermeasure in ARS. The EMA Orphan Drug Designation marks a new milestone for us, following our recent pre-IND discussions we had with the FDA to accelerate our development program. It is an important acknowledgment of the potential that NT-I7 holds in providing a beacon of hope for the treatment of ARS." ODD is a status assigned to a medicine intended for use against a rare disease or condition. The designation provides incentives to advance the development of treatments for rare diseases, including reduced fees for multiple steps in the development process, such as protocol assistance, marketing authorization applications, and inspections before authorization. About Acute Radiation Syndrome (ARS) Acute Radiation Syndrome (ARS) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (typically a matter of minutes or less). Examples of people who suffered from ARS are individuals exposed during the Hiroshima and Nagasaki atomic bombings, and the firefighters that responded after the Chernobyl Nuclear Power Plant incident in 1986.[1] About NT-I7 (efineptakin alfa) (rhIL-7-hyFc) NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications. About NeoImmuneTech, Inc. NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit . Forward-looking Statements The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the "Company") that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company's control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein. Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors. [1] SOURCE The NeoImmuneTech, Inc

免疫疗法放射疗法孤儿药临床研究

2024-06-03

·PRNewswire

NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancer Correlative analysis identified potentially predictive protein biomarkers associated with patients experiencing the most clinical benefits from combination treatment of NT-I7 and CPI Combination of NT-I7 and oncolytic virus demonstrates clear survival improvement in preclinical glioblastoma results ROCKVILLE, Md., June 3, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced promising interim results of its major clinical trial NIT-110 of NT-I7 (efineptakin alfa), at the 2024 American Society of Clinical Oncology (ASCO) global meeting held in Chicago, from May 31 to June 4. The company also presented two additional posters at the conference. NIT-110 is a foundational clinical trial for NT-I7 that aims to confirm the safety and efficacy of combining NT-I7 with pembrolizumab (Keytruda®) in solid tumors. The data presented at ASCO 2024 confirmed that the combination is safe and well-tolerated. Key findings from NIT-110 include: Pancreatic cancer - Data showed a median overall survival (mOS) of 11.1 months among the 48 pancreatic cancer patients included in the study. The mOS for pancreatic cancer patients who have received a second-line standard of care treatment is currently known to be 6.1 months[1]. This mOS improvement is particularly noteworthy considering that 93.75% of the patients are receiving the combination treatment as third-line or beyond. MSS colorectal cancer -The mOS for the 50 microsatellite-stable (MSS) colorectal cancer patients was 13.2 months. The mOS for the current standard of care treatment is 10.8 months[2]. These results underscore the improved efficacy of the NT-I7 and Keytruda combination over existing standard of care treatments. A separate poster from trial NIT-110 revealed a correlative analysis identifying a potentially predictive biomarker. These biomarkers may help identify patient populations more likely to benefit clinically from the NT-I7 and Keytruda combination. NeoImmuneTech is committed to further biomarker validation to enhance clinical outcomes. Additionally, a preclinical study presented at ASCO 2024 highlighted the combination of NT-I7 with an oncolytic virus (ZIKV) in a glioblastoma animal model. Results demonstrated a significant increase in tumor specific CD8 T cells in the tumor microenvironment, leading to improved survival rates. Furthermore, 80% of cases in the experimental group combining NT-I7 with immune checkpoint inhibitors resulted in complete tumor eradication. NT-I7 continues to show clinical benefits driven by T cell amplification when combined with immune therapies. NeoImmuneTech's CEO, Luke Oh, PhD, said: "We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat cancer. These findings confirm our promising preclinical data and open new pathways to further enhance clinical outcomes. We are actively discussing the next steps with Merck. The results presented at ASCO 2024 confirm our strategy to continue to develop NT-I7 in the larger and high-potential immuno-oncology market." Posters references: About Study NIT-110 NIT-110 is an open label Phase 2a clinical trial supported by Merck that aims to confirm the efficacy of combining NT-I7 with Keytruda in two solid tumors. Early results in 2022 had confirmed the efficacy of the combination in pancreatic cancer and MSS colorectal cancer patients, who are known to be unresponsive to immune checkpoint inhibitors alone. Consequently, 24 and 25 additional patients were recruited for each group, respectively, bringing the total to 48 pancreatic cancer patients and 50 MSS colorectal cancer patients currently undergoing clinical trials. Results presented at ASCO 2024 provide an updated analysis including the original and expansion cohorts. About NT-I7 (efineptakin alfa) (rhIL-7-hyFc) NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications. About NeoImmuneTech, Inc. NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit . Forward-looking Statements The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the "Company") that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company's control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein. Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors. [1] Wang-Gillam et al. Lancet. 2016. doi:10.1016/S0140-6736(15)00986-1 [2] Prager et al. N Engl J Med. 2023. doi:10.1056/NEJMoa221496 SOURCE The NeoImmuneTech, Inc

临床结果免疫疗法ASCO会议临床2期

2024-05-09

·生物探索

eBioMedicine | 中山大学罗镇华/冯旭阳/刘钧澄团队揭示黏膜相关恒定T细胞促进胆道闭锁疾病的胆管反应新机制

引言2024年4月27日，中山大学附属第一医院的罗镇华研究员、冯旭阳副研究员和小儿外科刘钧澄教授团队在柳叶刀Lancet的子刊eBioMedicine 上发表题为“Mucosal-associated invariant T cells promote ductular reaction through amphiregulin in biliary atresia”的研究论文，揭示黏膜相关恒定T细胞（Mucosal-associated invariant T cells, MAIT）异常活化、表现组织修复表型，并高表达生长因子AREG，促进胆道闭锁疾病的胆管反应的分子机制。胆道闭锁（Biliary atresia, BA）是一种严重的新生儿胆道疾病，胆管细胞损伤导致肝内外胆管阻塞，导致胆汁淤积，并造成肝纤维化[1]。虽然肝门肠吻合手术可以帮助胆汁引流，提高短期疗效[2]，但是，无论胆汁引流恢复程度如何，免疫介导的胆管损伤仍然持续存在[3]，而且与成人肝病相比，术后BA的肝纤维化进展迅速，导致术后两年内，至少75%的患儿将快速发展为肝硬化，需要进行肝移植[4]。胆管细胞损伤后，免疫应答启动，同时，胆管细胞增殖、肝脏祖细胞激活分化为反应性胆管细胞，参与组织修复。如果胆管细胞损伤持续存在，超过其自我修复过程，那么，胆管细胞异常增殖，并通过与各种浸润的免疫细胞相互作用诱导慢性炎症，最终导致肝脏的血管生成和纤维化，整个过程称为胆管反应（Ductular Reaction, DR）[5]。最初的免疫反应引起胆管细胞损伤和凋亡，随后，免疫反应一直持续到促纤维化反应的发生，最终免疫反应和胆管反应共同导致了肝纤维化。这其中胆道闭锁的免疫环境如何促进胆管反应和共同导致肝纤维化的发生是领域研究的热点。黏膜相关恒定T细胞（MAIT细胞）是一群非传统的T细胞亚群，在肝脏中非常丰富，占肝内T细胞的15-45%[6, 7]，功能多样，既有抗菌、抗病毒宿主防御作用，又可促进组织修复和维持稳态。目前，MAIT细胞是否参与胆道闭锁的免疫反应尚不清楚。作者探索MAIT细胞在胆道闭锁疾病中的功能，发现BA肝脏MAIT细胞高水平与低生存、胆管增殖和肝纤维化相关。进一步RNA测序分析显示，BA MAIT细胞呈现组织修复表型，上调组织修复相关生长因子AREG。机制研究表明，MAIT细胞通过AREG促进胆管细胞增殖和胆管类器官的生长，也促进和胆管类器官-LX-2混合模型的炎症因子和促纤维化分子表达。以上结果揭示，BA中MAIT细胞异常活化，高表达组织修复相关基因AREG，促进胆管反应。AREG高表达的MAIT细胞可以作为BA治疗的潜在靶点。该研究创新性构建体外细胞共培养模型，通过单细胞测序分析，发现这一系统的淋巴细胞群比例变化、基因表达谱与BA疾病相一致（图1），可以模拟BA免疫微环境。该模型首先通过RRV感染胆管细胞，随后与外周血单个核细胞共培养，建立方法相对简单，克服胆道闭锁疾病临床标本稀少的限制。因此，该系统可广泛应用于研究，有望成为研究胆道闭锁病理机制的新型工具。 RRV感染胆管细胞的体外细胞共培养模型模拟BA的免疫微环境(Credit: eBioMedicine)参考文献https://www-thelancet-com.libproxy1.nus.edu.sg/journals/ebiom/article/PIIS2352-3964(24)00173-7/fulltext[1] Ortiz-Perez A, Donnelly B, Temple H, Tiao G, Bansal R, and Mohanty S K; Innate Immunity and Pathogenesis of Biliary Atresia. Front Immunol, 2020, 11: 329.[2] Yang J, Gao W, Zhan J, and Feng J; Kasai procedure improves nutritional status and decreases transplantation-associated complications. Pediatr Surg Int, 2018, 34: 387-393.[3] Lampela H, Kosola, S., Heikkilä, P., Lohi, J., Jalanko, H., & Pakarinen, M. P; Native liver histology after successful portoenterostomy in biliary atresia. Journal after clinical gastroenterology, 2014, 48: 721-728.[4] Bezerra J A, Wells R G, Mack C L, Karpen S J, Hoofnagle J H, Doo E, and Sokol R J; Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century. Hepatology, 2018, 68: 1163-1173.[5] Sato K, Marzioni M, Meng F, Francis H, Glaser S, and Alpini G; Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances. Hepatology, 2019, 69: 420-430.[6] Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, Milder M, Bourhis L L, Soudais C, and Treiner E; Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood, 2011, 117: 1250-1259.[7] Tang X Z, Jo J, Tan A T, Sandalova E, Chia A, Tan K C, Lee K H, Gehring A J, De Libero G, and Bertoletti A; IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol, 2013, 190: 3142-52.责编|探索君排版|探索君文章来源|“iNature”End往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文Nature | 破除传统：为何我们需要重新思考肿瘤的命名方式热文Nature | 2024年值得关注的七项技术热文Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文CRISPR技术进化史 | 24年Cell综述

细胞疗法

100 项与 Interleukin-7(Cytheris SA) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11997

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	美国	RevImmune, Inc.	2022-01-30
急性髓性白血病	临床2期	美国	National Cancer Institute	2020-09-29
骨髓增生异常综合征	临床2期	美国	National Cancer Institute	2020-09-29
费城染色体阳性慢性粒细胞白血病	临床2期	美国	National Cancer Institute	2020-09-29
伯基特淋巴瘤	临床2期	法国	RevImmune, Inc.	2020-06-08
新型冠状病毒“奥密克戎”变异株感染	临床2期	法国	RevImmune, Inc.	2020-06-08
淋巴细胞减少	临床2期	法国	RevImmune, Inc.	2020-06-08
晚期尿路上皮癌	临床2期	美国	National Cancer Institute	2019-06-05
转移性尿道尿路上皮癌	临床2期	美国	National Cancer Institute	2019-06-05
转移性尿路上皮癌	临床2期	美国	National Cancer Institute	2019-06-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03513952 (ASCO_GU2024)	临床2期	转移性尿路上皮癌	47	Atezolizumab + CYT107	觸衊積鏇鏇衊獵膚鹹範(積壓壓醖積艱廠觸夢夢) = 淵憲簾範選簾鹽膚選糧積壓襯膚築鏇遞顧齋鑰 (顧製鏇獵簾醖齋願繭襯 ) 更多	积极	2024-01-25
				Atezolizumab	觸衊積鏇鏇衊獵膚鹹範(積壓壓醖積艱廠觸夢夢) = 願夢繭壓鑰築襯構鬱鬱積壓襯膚築鏇遞顧齋鑰 (顧製鏇獵簾醖齋願繭襯 ) 更多
NCT03941769 (2018-0674, CTgov)	临床1/2期	急性髓性白血病 \| 费城染色体阳性慢性粒细胞白血病 \| 骨髓增生异常综合征	1	Recombinant Interleukin-7	齋醖繭簾簾鏇蓋構夢壓(壓築鑰鬱積構壓選鹽獵) = 襯簾壓廠繭製襯積齋膚鑰餘鏇鏇範範製糧選膚 (齋壓構繭簾鬱製鑰壓範, 衊範鬱淵觸襯餘顧觸選 ~ 淵淵醖顧蓋選願鏇襯繭) 更多	-	2023-08-01
NCT02640807 (CTgov)	临床2期	脓毒症	27	Interleukin-7 (CYT107 High Frequency)	廠鹹築餘夢觸衊願餘夢(憲鹽鬱襯願壓積獵築窪) = 鏇鹹餘顧齋廠顧夢簾襯鏇醖蓋廠選鏇網鑰衊範 (醖願憲鑰簾鏇鑰鹽製網, 顧選觸鹽淵積廠遞製鹹 ~ 壓範鏇窪築構淵構蓋簾) 更多	-	2020-07-09
				Placebo+Interleukin-7 (CYT107 Low Frequency)	廠鹹築餘夢觸衊願餘夢(憲鹽鬱襯願壓積獵築窪) = 窪獵鏇鏇艱獵繭衊範製鏇醖蓋廠選鏇網鑰衊範 (醖願憲鑰簾鏇鑰鹽製網, 衊淵繭獵顧鹽構壓膚積 ~ 鹹願壓鹹鏇選艱夢襯壓) 更多
NCT01881867 (P298, CTgov)	临床2期	转移性去势抵抗性前列腺癌 \| 前列腺癌转移	54	sipuleucel-T (Cohort I (no Therapy))	簾餘積觸顧衊鑰鹽網繭(願艱積築憲夢顧鑰夢網) = 積積夢衊製壓壓窪鏇齋餘繭顧壓餘衊獵觸鹽鹹 (齋顧齋壓餘襯獵網膚遞, 壓憲醖餘製製築蓋鏇觸 ~ 鬱鬱遞簾鹽鹽醖構憲鏇) 更多	-	2018-12-11
				Laboratory Biomarker Analysis+Glycosylated Recombinant Human Interleukin-7 (Cohort II (Glycosylated Recombinant Human Interleukin-7))	簾餘積觸顧衊鑰鹽網繭(願艱積築憲夢顧鑰夢網) = 衊蓋鑰淵醖築艱夢觸艱餘繭顧壓餘衊獵觸鹽鹹 (齋顧齋壓餘襯獵網膚遞, 選蓋憲襯顧構窪選醖遞 ~ 鑰觸獵鹹獵獵夢餘蓋廠) 更多
INSPIRE II, INSPIRE III (Pubmed \| Clin Infect Dis)	临床2期	HIV感染	107	recombinant human interleukin 7 (r-hIL-7)	齋廠簾遞顧淵積餘廠蓋(製衊繭獵窪醖鹽鑰窪觸) = 製壓觸獵顧鑰夢膚襯網遞憲衊繭淵範鬱膚顧糧 (築獵窪壓積襯觸觸淵鏇 )	-	2016-05-01
ANA2015	N/A	-	-	Intravenous Immunoglobulin	簾觸衊網餘壓鹹願鹽鏇(製壓壓範製鏇鏇廠糧憲) = 觸簾鏇蓋膚製醖網遞糧蓋艱蓋襯醖網蓋膚鑰襯 (鏇遞廠淵鹽糧構願糧膚 ) 更多	积极	2015-09-25
				Intravenous Methylprednisolone	簾觸衊網餘壓鹹願鹽鏇(製壓壓範製鏇鏇廠糧憲) = 鹽鑰願鏇醖廠製壓繭鬱蓋艱蓋襯醖網蓋膚鑰襯 (鏇遞廠淵鹽糧構願糧膚 ) 更多
NCT01368107 (ELYPSE-7, ASCO2014)	临床2期	转移性乳腺癌	20	IL-7 (CYT107)	艱選觸壓齋醖顧築顧顧(壓範獵願繭淵鏇鹽醖鑰) = 觸窪鑰淵觸鏇顧窪齋構簾夢鬱簾艱繭醖築齋鬱 (鏇衊築壓簾獵糧顧獵鬱 )	积极	2014-05-20
				Placebo	艱選觸壓齋醖顧築顧顧(壓範獵願繭淵鏇鹽醖鑰) = 築壓獵醖獵網憲餘繭築簾夢鬱簾艱繭醖築齋鬱 (鏇衊築壓簾獵糧顧獵鬱 )
NCT01368107 (Pubmed \| Clin Infect Dis)	临床1期	HIV感染	24	Recombinant Human Interleukin 7 (rhIL-7)	壓鏇壓膚觸鑰憲鏇繭願(顧糧淵夢襯膚齋繭積觸) = 積構膚築鬱衊選廠餘蓋鏇鏇廠鑰衊觸廠積獵鹹 (鬱醖構齋鏇廠觸衊積廠 )	-	2012-07-01